Listed

Protalix BioTherapeutics, Inc.: Form 10-Q/A for the period ended Mar 31, 2018

Filed with the SEC on Mar 18, 2019 and accepted by EDGAR at Mar 18, 2019, 07:07 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2018-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Cost of revenue3 months2018-01-01 to 2018-03-31$2.9mus-gaap:CostOfRevenue
Research and development3 months2018-01-01 to 2018-03-31$7.3mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2018-01-01 to 2018-03-31$2.5mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2018-01-01 to 2018-03-31−$5.2mus-gaap:OperatingIncomeLoss
Net income3 months2018-01-01 to 2018-03-31−$7.2mus-gaap:NetIncomeLoss
Diluted EPS3 months2018-01-01 to 2018-03-31−$0.05us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow3 months2018-01-01 to 2018-03-31−$9.4mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2018-01-01 to 2018-03-31$249.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2018-03-31$41.3mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2018-03-31$55.7mus-gaap:AssetsCurrent
Total assetsAt period end2018-03-31$64.8mus-gaap:Assets
Current liabilitiesAt period end2018-03-31$24.1mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2018-03-31$100.2mus-gaap:Liabilities
Shareholders' equityAt period end2018-03-31−$35.4mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001144204-19-014450. Last ingested by Listed: Nov 10, 2026, 16:48 ET. Listed shows no prices and gives no investment advice.